NCT02106845 - Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 22, 2014

Primary Completion Date

April 27, 2015

Study Completion Date

June 12, 2018

Conditions

Neoplasms

Interventions

DRUG

Digoxin

Single dose of digoxin 0.5 mg (2 tablets 0.25 mg) orally without and with regorafenib

DRUG

Rosuvastatin

Single dose of rosuvastatin 5mg (1 tablet 5 mg) without and with regorafenib 160 mg q.d. (4 tablets 40 mg)

DRUG

Regorafenib (Stivarga, BAY73-4506)

Once daily orally 160 mg (4 tablets 40 mg)

Trial Locations (5)

Budapest

Budapest

Herne

Frankfurt am Main

Freiburg im Breisgau